Leo Pharma this month launched two new Twitter accounts to continue efforts that include publishing its social media principles. 

These state the company's desire to share information but, as would be expected given European marketing codes, won't see it "discuss or provide diagnosis of a skin condition". 

"Due to regulations, we cannot discuss pharmaceutical products. All content must be factual and non-promotional," the social media principles state.  Unsurprisingly too, the company plans to verify any external websites and links before it shares them.

The principles go on to explain that the company plans to be social in its use if social media (something that pharma often struggles with): "We will endeavour to respond to @ mentions and/or replies and ensure that any factually incorrect information shared is corrected as soon as possible.

"As a pharmaceutical company, Leo Pharma is not in a position to diagnose a skin condition or provide advice on how they should be managed, including recommending any treatments." 

Nevertheless, the company, which earlier this year submitted an aerosol foam treatment for plaque psoriasis for US approval, does want to have a dialogue on skin issues.

Adding to the @LeoHealthySkin Twitter account it started last September, Leo this month started tweeting from its new corporate @LeoPharmaCh account and the psoriasis-focused @LeoPharmaCh_pso.

Digital inspiration for pharma on mobile, social media, strategy, best practice, regulations and more